Waldenström macroglobulinemia is a rare hematological cancer characterized by an excess of abnormal lymphoplasmacytic cells in the bone marrow and is classified as a lymphoplasmacytic lymphoma. Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the treatment of Waldenstrom’s macroglobulinemia in the era of immunotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).